These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23767436)

  • 21. Abuse liability assessment in preclinical drug development: predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models.
    Teuns GB; Geys HM; Geuens SM; Stinissen P; Meert TF
    J Pharmacol Toxicol Methods; 2014; 70(3):295-309. PubMed ID: 24632211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Gammahydroxybutyrate must remain available for patients with narcolepsy].
    Lammers GJ; van Dijk JG; Ferrari MD; van Gerven JM; Declerck AC; Troost J
    Ned Tijdschr Geneeskd; 1999 Oct; 143(41):2062-3. PubMed ID: 10560549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of methylphenidate among students: the future of enhancement?
    Outram SM
    J Med Ethics; 2010 Apr; 36(4):198-202. PubMed ID: 20338928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Changing Drug Culture: Use and Misuse of Cognition-Enhancing Drugs.
    Albertson TE; Chenoweth JA; Colby DK; Sutter ME
    FP Essent; 2016 Feb; 441():25-9. PubMed ID: 26881770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evaluation of the abuse potential of modafinil using methylphenidate as a reference.
    Jasinski DR
    J Psychopharmacol; 2000 Mar; 14(1):53-60. PubMed ID: 10757254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacological cognitive enhancement from a perspective of misuse and addiction].
    Franke AG; Soyka M
    Fortschr Neurol Psychiatr; 2015 Feb; 83(2):83-90. PubMed ID: 25723772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 'Uppers' keep going up.
    Ghodse H
    Br J Psychiatry; 2007 Oct; 191():279-81. PubMed ID: 17906235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attention deficit hyperactivity disorder in prison.
    Ghanizadeh A; Akhondzadeh S
    J Am Acad Psychiatry Law; 2009; 37(2):278. PubMed ID: 19535565
    [No Abstract]   [Full Text] [Related]  

  • 29. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents.
    Williams RJ; Goodale LA; Shay-Fiddler MA; Gloster SP; Chang SY
    Am J Addict; 2004; 13(4):381-9. PubMed ID: 15370936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Towards responsible use of cognitive-enhancing drugs by the healthy.
    Greely H; Sahakian B; Harris J; Kessler RC; Gazzaniga M; Campbell P; Farah MJ
    Nature; 2008 Dec; 456(7223):702-5. PubMed ID: 19060880
    [No Abstract]   [Full Text] [Related]  

  • 31. Sociological approaches to the study of drug use and drug policy.
    Stevens A
    Int J Drug Policy; 2011 Nov; 22(6):399-403. PubMed ID: 22078055
    [No Abstract]   [Full Text] [Related]  

  • 32. Is the non-medical use of prescription stimulants a problem in Australia?
    Lucke JC; Hall WD
    Med J Aust; 2012 Aug; 197(3):145. PubMed ID: 22860781
    [No Abstract]   [Full Text] [Related]  

  • 33. Methamphetamine precursor regulation: are we controlling or diverting the drug problem?
    McKetin R
    Addiction; 2008 Apr; 103(4):521-3. PubMed ID: 18339098
    [No Abstract]   [Full Text] [Related]  

  • 34. The consumable vice: caffeine, public health, and the law.
    Hodge JG; Scanlon M; Corbe A; Sorensen A
    J Contemp Health Law Policy; 2010; 27(1):76-119. PubMed ID: 21322400
    [No Abstract]   [Full Text] [Related]  

  • 35. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans.
    Stoops WW; Glaser PE; Fillmore MT; Rush CR
    J Psychopharmacol; 2004 Dec; 18(4):534-43. PubMed ID: 15582920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New Ritalin ad blitz makes parents jumpy.
    Novak V
    Time; 2001 Sep; 158(10):62-3. PubMed ID: 11558351
    [No Abstract]   [Full Text] [Related]  

  • 37. [Central nervous system stimulants and their potential risk of abuse in hyperkinetic disorders].
    Aanonsen NO
    Tidsskr Nor Laegeforen; 1999 Nov; 119(27):4040-2. PubMed ID: 10613094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitization and cross-sensitization after chronic treatment with methylphenidate in adolescent Wistar rats.
    Valvassori SS; Frey BN; Martins MR; Réus GZ; Schimidtz F; Inácio CG; Kapczinski F; Quevedo J
    Behav Pharmacol; 2007 May; 18(3):205-12. PubMed ID: 17426484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Characteristics of university students using stimulants for cognitive enhancement: a pilot study].
    Franke AG; Schwarze CE; Christmann M; Bonertz C; Hildt E; Lieb K
    Psychiatr Prax; 2012 May; 39(4):174-80. PubMed ID: 22318482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications.
    Jain R; Stark JG
    Postgrad Med; 2016 Sep; 128(7):672-81. PubMed ID: 27467139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.